{
    "eid": "2-s2.0-85122965055",
    "title": "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
    "cover-date": "2022-01-24",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Immunology and Microbiology (all)",
            "@code": "2400",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        },
        {
            "@_fa": "true",
            "$": "Public Health, Environmental and Occupational Health",
            "@code": "2739",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Booster dose",
        "COVID-19",
        "Immunogenicity",
        "Inactivated vaccine",
        "Virus vector"
    ],
    "authors": [
        "Ritthideach Yorsaeng",
        "Nungruthai Suntronwong",
        "Harit Phowatthanasathian",
        "Suvichada Assawakosri",
        "Sitthichai Kanokudom",
        "Thanunrat Thongmee",
        "Preeyaporn Vichaiwattana",
        "Chompoonut Auphimai",
        "Lakkhana Wongsrisang",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Sirapa Klinfueng",
        "Natthinee Sudhinaraset",
        "Nasamon Wanlapakorn",
        "Yong Poovorawan"
    ],
    "citedby-count": 38,
    "ref-count": 26,
    "ref-list": [
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines",
        "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial",
        "COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials",
        "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant",
        "Hundreds of Thais inoculated with Sinovac are infected as cases spike in Southeast Asia",
        "SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020",
        "Effectiveness of an Inactivated SARS-CoV-2 Vaccine",
        "A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)",
        "Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients",
        "Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults",
        "IgA dominates the early neutralizing antibody response to SARS-CoV-2",
        "Highly-specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA",
        "Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2",
        "Enhanced SARS-CoV-2 neutralization by dimeric IgA",
        "Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study",
        "Sex differences in immune responses"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Dusit",
            "@id": "127564353",
            "affilname": "FRS(T)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127564353",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}